NasdaqCM:IMNMBiotechs
Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations
Immunome plans to present full Phase 3 RINGSIDE trial data for varegacestat in desmoid tumor patients at the 2026 ASCO Annual Meeting.
The company expects to file a New Drug Application with the FDA for varegacestat after the ASCO presentation.
The update highlights progress toward a potential new treatment option for this rare soft tissue tumor.
For investors tracking Immunome, ticker NasdaqCM:IMNM, this update centers on a late stage program that could influence the company’s future...